Insulin growth factor receptor-1 expression and loss of PTEN protein predict early recurrence in triple-negative breast cancer

Histopathology

Volumn 61, Issue 4, 2012, Pages 652-659

  Iqba, Jabed ^a   Thike, Aye Aye ^a   Cheok, Poh Yian ^a   Tse, Gary Man Kit ^b   Tan, Puay Hoon ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Basal like; IGFR 1; PAKT; PTEN; Targeted treatment; Triple negative

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; PTEN PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CANCER TISSUE; CYTOPLASM; DISEASE FREE SURVIVAL; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER; BIOSYNTHESIS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PTEN PHOSPHOHYDROLASE; RECEPTOR, IGF TYPE 1; TISSUE ARRAY ANALYSIS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84871919545     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04255.x     Document Type: Article

References (39)

1. deGraffenried LA, Fulcher L, Friedrichs WE et al. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann. Oncol. 2004; 15; 1510-1516.
2. Cappuzzo F, Toschi L, Tallini G et al. Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Ann. Oncol. 2006; 17; 1120-1127.
3. Tsai E-M, Wang S-C, Lee J-N, Mien-Hung M-C. Akt Activation by estrogen in estrogen receptor-negative breast cancer cells. Cancer Res. 2001; 61; 8390-8392.
4. Hartog H, Horlings HM, Vegt BV et al. Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma. Breast Cancer Res. Treat. 2011; 129; 725-736.
5. Creighton CJ, Casa A, Lazard Z et al. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J. Clin. Oncol. 2008; 26; 4078-4085.
6. Yamamoto O, Gomyo Y, Hirooka Y et al. Expression of phospho- Akt and PTEN proteins in human breast cancer in relation to tumor progression and patient survival. Yonago Acta Med. 2006; 49; 19-27.
7. Umemura S, Yoshida S, Ohta Y et al. Increased phosphorylation of Akt in triple-negative breast cancers. Cancer Sci. 2007; 98; 1889-1892.
8. Bose S, Chandran S, Mirocha JM, Bose N. The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod. Pathol. 2006; 19; 238-245.
9. Turner BC, Haffty BG, Narayanan L et al. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res. 1997; 57; 3079-3083.
10. Rocha RL, Hilsenbeck SG, Jackson JG et al. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and diseasefree survival. Clin. Cancer Res. 1997; 3; 103-109.
11. Marty B, Maire V, Gravier E et al. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res. 2008; 10; R101.
12. Miller BS, Yee D. Type I insulin-like growth factor receptor as a therapeutic target in cancer. Cancer Res. 2005; 65; 10123-10127.
13. Gera JF, Mellinghoff IK, Shi Y et al. AKT activity determines sensitivity to mTOR inhibitors by regulating cyclin D1 and c-myc expression. J. Biol. Chem. 2004; 279; 2737-2746.
14. Badve S, Collins NR, Bhat-Nakshatri P et al. Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implications. Am. J. Pathol. 2010; 176; 2139-2149.
15. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl Acad. Sci. USA 1999; 96; 4240-4245.
16. Thike AA, Cheok PY, Jara-Lazaro AR et al. Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod. Pathol. 2010; 23; 123-133.
17. Hammond MEH, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch. Pathol. Lab. Med. 2010; 134; 907-922.
18. Hudis CA, Barlow WE, Costantino JP et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J. Clin. Oncol. 2007; 25; 2127-2132.
19. Shen WH, Balajee AS, Wang J et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007; 128; 157-170.
20. Miller TW, Pe'rez-Torres M, Narasanna A. Loss of Phosphatase and tensin homologue deleted on chromosome 10 engages ErbB3 and IGF-IR signaling to promote antiestrogen resistance in breast cancer. Cancer Res. 2009; 69; 4192-4201.
21. Depowski PL, Rosenthal SI, Ross JS. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod. Pathol. 2001; 14; 672-676.
22. Shi W, Zhang X, Pintilie M et al. Dysregulated PTEN-PKB and negative receptor status in human breast cancer. Int. J. Cancer 2003; 104; 195-203.
23. Nakatani K, Thompson DA, Barthel A. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J. Biol. Chem. 1999; 274; 21528-21532.
24. Railo MJ, Von Smitten K, Pekonen F. The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients. Eur. J. Cancer 1994; 30A; 307-311.
25. Steelman LS, Navolanic PM, Sokolosky ML et al. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene 2008; 27; 4086-4095.
26. Thike AA, Iqbal J, Cheok PY et al. Triple negative breast cancer: outcome correlation with immunohistochemical detection of basal markers. Am. J. Surg. Pathol. 2010; 34; 956-964.
27. Cullen KJ, Yee D, Sly WS et al. Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res. 1990; 50; 48-53.
28. Scartozzi M, Bianconi M, Maccaroni E et al. Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. Curr. Opin. Mol. Ther. 2010; 12; 361-371.
29. Shoman N, Klassen S, McFadden A et al. Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. Mod. Pathol. 2005; 18; 250-259.
30. Litzenburger BC, Anna Tsimelzo A, Creighton CJ et al. High IGFIR activity in triple-negative breast cancer cell lines and tumor grafts correlates with sensitivity to anti-IGF-IR therapy. Clin. Cancer Res. 2011; 17; 2314-2327.
31. Rakha EA, El-Sayed ME, Green AR et al. Prognostic markers in triple-negative breast cancer. Cancer 2007; 109; 25-32.
32. Rowinsky EK, Youssoufian H, Tonra JR et al. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin. Cancer Res. 2007; 13; 5549-5555.
33. Saal LH, Johansson P, Holmb K et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc. Natl Acad. Sci. USA 2007; 104; 7564-7569.
34. Nagata Y, Lan K, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6; 119-127.
35. Capodanno A, Camerini A, Orlandini C et al. Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma. Hum. Pathol. 2009; 40; 1408-1417.
36. Hewish M, Chau I, Cunningham D. Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat. Anti-Cancer Drug Discov. 2009; 4; 54-72.
37. Guix M, Faber AC, Wang SR et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J. Clin. Invest. 2008; 118; 2609-2619.
38. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12; 9-22.
39. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell 2008; 133; 403-414.